NYKODE THERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.1 NOK | +1.55% |
|
+1.08% | -38.79% |
| Sales 2024 * | 157M 14.35M | Sales 2025 * | 190M 17.35M | Capitalization | 4.21B 385M |
|---|---|---|---|---|---|
| Net income 2024 * | -613M -56M | Net income 2025 * | -735M -67.14M | EV / Sales 2024 * | 18.8 x |
| Net cash position 2024 * | 1.25B 115M | Net cash position 2025 * | 1.01B 92.18M | EV / Sales 2025 * | 16.9 x |
| P/E ratio 2024 * |
-6.93
x | P/E ratio 2025 * |
-6.21
x | Employees | 172 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nykode Therapeutics
More press releases
| 1 day | +1.55% | ||
| 1 week | +1.08% | ||
| Current month | -12.61% | ||
| 1 month | -14.04% | ||
| 3 months | -31.13% | ||
| 6 months | -22.21% | ||
| Current year | -38.79% |
1 week
12.50
13.68
1 month
12.3815.36
Current year
12.3821.40
1 year
12.3830.86
3 years
12.3889.50
5 years
12.3893.00
10 years
12.3893.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
| Director/Board Member | 64 | - | |
| Director/Board Member | - | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 152 M€ | -3.71% | - | |
| 0.00% | 26 M€ | -4.70% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 13.1 | +1.55% | 181 285 |
| 24-04-25 | 12.9 | -3.01% | 600,010 |
| 24-04-24 | 13.3 | -0.82% | 507,883 |
| 24-04-23 | 13.41 | +1.90% | 425,178 |
| 24-04-22 | 13.16 | +1.54% | 538,941 |
Real-time Oslo Bors, April 26, 2024 at 04:09 am EDT
More quotes
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Calendar
2024-05-13
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.9
NOK
Average target price
43
NOK
Spread / Average Target
+233.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.79% | 383M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.99% | 22.02B | |
| -17.84% | 20.9B | |
| -9.44% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- VACC Stock
